Single User License
INR 135860
Site License
INR 271720
Corporate User License
INR 407580

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Neuroblastoma-Pipeline Review, H1 2015

Neuroblastoma-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Neuroblastoma-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Neuroblastoma-Pipeline Review, H1 2015', provides an overview of the Neuroblastoma's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Neuroblastoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neuroblastoma and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Neuroblastoma

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Neuroblastoma and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Neuroblastoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Neuroblastoma pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Neuroblastoma

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Neuroblastoma pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Neuroblastoma Overview 10

Therapeutics Development 11

Pipeline Products for Neuroblastoma-Overview 11

Pipeline Products for Neuroblastoma-Comparative Analysis 12

Neuroblastoma-Therapeutics under Development by Companies 13

Neuroblastoma-Therapeutics under Investigation by Universities/Institutes 18

Neuroblastoma-Pipeline Products Glance 20

Late Stage Products 20

Clinical Stage Products 21

Early Stage Products 22

Neuroblastoma-Products under Development by Companies 23

Neuroblastoma-Products under Investigation by Universities/Institutes 28

Neuroblastoma-Companies Involved in Therapeutics Development 30

Ability Pharma, SL 30

Acetylon Pharmaceuticals, Inc. 31

Advanced Accelerator Applications SA 32

Aeterna Zentaris Inc. 33

Ampio Pharmaceuticals, Inc. 34

APEIRON Biologics AG 35

Aptose Biosciences Inc. 36

AstraZeneca Plc 37

Bellicum Pharmaceuticals, Inc. 38

Bexion Pharmaceuticals, LLC. 39

BioLineRx, Ltd. 40

Bionucleon Srl 41

Cebiotex, S.L. 42

Celgene Corporation 43

Chugai Pharmaceutical Co., Ltd. 44

Cleveland BioLabs, Inc. 45

CureFAKtor Pharmaceuticals, LLC 46

DEKK-TEC, Inc. 47

Errant Gene Therapeutics, LLC 48

F. Hoffmann-La Roche Ltd. 49

Gamida Cell Ltd. 50

Ignyta, Inc. 51

Juno Therapeutics Inc. 52

Lindis Biotech GmbH 53

MabVax Therapeutics Holdings, Inc. 54

Merck & Co., Inc. 55

Merrimack Pharmaceuticals, Inc. 56

Netris Pharma S.A.S. 57

Novartis AG 58

Novogen Limited 59

Pono Pharma 60

Progenics Pharmaceuticals, Inc. 61

Recombio S.L 62

Sareum Holdings Plc 63

Shionogi & Co., Ltd. 64

Sutro Biopharma, Inc. 65

Teva Pharmaceutical Industries Limited 66

Threshold Pharmaceuticals, Inc. 67

United Therapeutics Corporation 68

Neuroblastoma-Therapeutics Assessment 69

Assessment by Monotherapy Products 69

Assessment by Combination Products 70

Assessment by Target 71

Assessment by Mechanism of Action 76

Assessment by Route of Administration 80

Assessment by Molecule Type 82

Drug Profiles 84

1-B7-Drug Profile 84

31-F9-Drug Profile 85

ABTL-0812-Drug Profile 86

ACY-957-Drug Profile 88

AMXT-1501 + eflornithine hydrochloride-Drug Profile 89

APN-301-Drug Profile 91

APN-311-Drug Profile 93

ATM-3507-Drug Profile 95

AZ-64-Drug Profile 96

BACPT-DP-Drug Profile 97

bevacizumab-Drug Profile 99

BL-8040-Drug Profile 104

BN-210-Drug Profile 106

BPX-701-Drug Profile 107

BXQ-350-Drug Profile 108

CCT-137690-Drug Profile 110

CCT-244747-Drug Profile 111

CEB-01-Drug Profile 113

Cell Therapy for GD2 Expressing Solid Tumors-Drug Profile 114

Cell Therapy for Neuroblastoma-Drug Profile 115

Cell Therapy to Target GD2 for Neuroblastoma-Drug Profile 116

Cell Therapy to Target GD2 for Neuroblastoma-Drug Profile 117

celyvir-Drug Profile 118

CEP-28122-Drug Profile 120

CFAKC-4-Drug Profile 121

CFAKY-15-Drug Profile 122

CG-1521-Drug Profile 123

cVE-199-Drug Profile 124

Dendritic Cell Therapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology-Drug Profile 125

dinutuximab-Drug Profile 126

Drugs to Activate Caspase 3 for Oncology-Drug Profile 128

Edotreotide Labeled Yttrium 90-Drug Profile 129

eflornithine hydrochloride-Drug Profile 131

eh8B6-Drug Profile 133

entrectinib-Drug Profile 134

evofosfamide-Drug Profile 136

firtecan pegol-Drug Profile 144

FSEC-Drug Profile 146

iobenguane sulfate I 131-Drug Profile 147

irinotecan sucrosofate liposomal-Drug Profile 149

JCAR-023-Drug Profile 152

Lutathera-Drug Profile 153

M-606-Drug Profile 155

Monoclonal Antibody to Inhibit GD2 for Oncology-Drug Profile 156

Monoclonal Antibody to Target CD3 for Neuroblastoma-Drug Profile 157

Monoclonal Antibody to Target Ganglioside GD2 for Neuroblastom-Drug Profile 158

Monoclonal Antibody to Target GD2 and CD3 for Neuroblastoma-Drug Profile 160

Monoclonal Antibody to Target GD2 for Neuroblastoma-Drug Profile 161

NCE-001-Drug Profile 162

NTX-010-Drug Profile 163

Oncolytic Virus for Oncology-Drug Profile 165

P-937-Drug Profile 166

paclitaxel albumin bound-Drug Profile 167

pazopanib hydrochloride-Drug Profile 170

pembrolizumab-Drug Profile 175

Peptide to Inhibit HDAC for Neuroblastoma-Drug Profile 182

perifosine-Drug Profile 183

racotumomab-Drug Profile 186

Recombinant Protein to Inhibit HDAC for Neuroblastoma-Drug Profile 188

ribociclib-Drug Profile 189

RKS-262-Drug Profile 192

RNAi Oligonucleotide for Oncology-Drug Profile 193

RNAi Oligonucleotides for Neuroblastoma-Drug Profile 194

RSF-701-Drug Profile 195

S-588410-Drug Profile 196

SAR-020106-Drug Profile 197

SF-1126-Drug Profile 199

Small Molecule to Target Netrin-1 Ligand for Oncology-Drug Profile 201

Small Molecules for Neuroblastoma-Drug Profile 202

Small Molecules for Neuroblastoma-Drug Profile 203

Small Molecules to Antagonize ALK for Oncology-Drug Profile 204

Small Molecules to Inhibit Aurora and ALK Kinase for Oncology-Drug Profile 205

Small Molecules to Inhibit Aurora Kinase and FLT3 Kinase for Oncology-Drug Profile 206

SRX-2523-Drug Profile 208

Stem Cells to Activate Natural Killer Cell for Adoptive Cell-Mediated Therapy-Drug Profile 210

Syrbactins-Drug Profile 211

TL-118-Drug Profile 212

TPI-287-Drug Profile 214

TR-100-Drug Profile 216

TRBS-07-Drug Profile 217

Trilexium-Drug Profile 218

Vaccine for Neuroblastoma-Drug Profile 219

Vaccine for Neuroblastoma-Drug Profile 221

Vaccine for Neuroblastoma-Drug Profile 222

Vaccine for Neuroblastoma-Drug Profile 223

Neuroblastoma-Recent Pipeline Updates 224

Neuroblastoma-Dormant Projects 287

Neuroblastoma-Discontinued Products 290

Neuroblastoma-Product Development Milestones 291

Featured News & Press Releases 291

Appendix 301

Methodology 301

Coverage 301

Secondary Research 301

Primary Research 301

Expert Panel Validation 301

Contact Us 301

Disclaimer 302

List of Tables

Number of Products under Development for Neuroblastoma, H1 2015 17

Number of Products under Development for Neuroblastoma-Comparative Analysis, H1 2015 18

Number of Products under Development by Companies, H1 2015 20

Number of Products under Development by Companies, H1 2015 (Contd..1) 21

Number of Products under Development by Companies, H1 2015 (Contd..2) 22

Number of Products under Development by Companies, H1 2015 (Contd..3) 23

Number of Products under Investigation by Universities/Institutes, H1 2015 25

Comparative Analysis by Late Stage Development, H1 2015 26

Comparative Analysis by Clinical Stage Development, H1 2015 27

Comparative Analysis by Early Stage Development, H1 2015 28

Products under Development by Companies, H1 2015 29

Products under Development by Companies, H1 2015 (Contd..1) 30

Products under Development by Companies, H1 2015 (Contd..2) 31

Products under Development by Companies, H1 2015 (Contd..3) 32

Products under Development by Companies, H1 2015 (Contd..4) 33

Products under Investigation by Universities/Institutes, H1 2015 34

Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 35

Neuroblastoma-Pipeline by Ability Pharma, SL, H1 2015 36

Neuroblastoma-Pipeline by Acetylon Pharmaceuticals, Inc., H1 2015 37

Neuroblastoma-Pipeline by Advanced Accelerator Applications SA, H1 2015 38

Neuroblastoma-Pipeline by Aeterna Zentaris Inc., H1 2015 39

Neuroblastoma-Pipeline by Ampio Pharmaceuticals, Inc., H1 2015 40

Neuroblastoma-Pipeline by APEIRON Biologics AG, H1 2015 41

Neuroblastoma-Pipeline by Aptose Biosciences Inc., H1 2015 42

Neuroblastoma-Pipeline by AstraZeneca Plc, H1 2015 43

Neuroblastoma-Pipeline by Bellicum Pharmaceuticals, Inc., H1 2015 44

Neuroblastoma-Pipeline by Bexion Pharmaceuticals, LLC., H1 2015 45

Neuroblastoma-Pipeline by BioLineRx, Ltd., H1 2015 46

Neuroblastoma-Pipeline by Bionucleon Srl, H1 2015 47

Neuroblastoma-Pipeline by Cebiotex, S.L., H1 2015 48

Neuroblastoma-Pipeline by Celgene Corporation, H1 2015 49

Neuroblastoma-Pipeline by Chugai Pharmaceutical Co., Ltd., H1 2015 50

Neuroblastoma-Pipeline by Cleveland BioLabs, Inc., H1 2015 51

Neuroblastoma-Pipeline by CureFAKtor Pharmaceuticals, LLC, H1 2015 52

Neuroblastoma-Pipeline by DEKK-TEC, Inc., H1 2015 53

Neuroblastoma-Pipeline by Errant Gene Therapeutics, LLC, H1 2015 54

Neuroblastoma-Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 55

Neuroblastoma-Pipeline by Gamida Cell Ltd., H1 2015 56

Neuroblastoma-Pipeline by Ignyta, Inc., H1 2015 57

Neuroblastoma-Pipeline by Juno Therapeutics Inc., H1 2015 58

Neuroblastoma-Pipeline by Lindis Biotech GmbH, H1 2015 59

Neuroblastoma-Pipeline by MabVax Therapeutics Holdings, Inc., H1 2015 60

Neuroblastoma-Pipeline by Merck & Co., Inc., H1 2015 61

Neuroblastoma-Pipeline by Merrimack Pharmaceuticals, Inc., H1 2015 62

Neuroblastoma-Pipeline by Netris Pharma S.A.S., H1 2015 63

Neuroblastoma-Pipeline by Novartis AG, H1 2015 64

Neuroblastoma-Pipeline by Novogen Limited, H1 2015 65

Neuroblastoma-Pipeline by Pono Pharma, H1 2015 66

Neuroblastoma-Pipeline by Progenics Pharmaceuticals, Inc., H1 2015 67

Neuroblastoma-Pipeline by Recombio S.L, H1 2015 68

Neuroblastoma-Pipeline by Sareum Holdings Plc, H1 2015 69

Neuroblastoma-Pipeline by Shionogi & Co., Ltd., H1 2015 70

Neuroblastoma-Pipeline by Sutro Biopharma, Inc., H1 2015 71

Neuroblastoma-Pipeline by Teva Pharmaceutical Industries Limited, H1 2015 72

Neuroblastoma-Pipeline by Threshold Pharmaceuticals, Inc., H1 2015 73

Neuroblastoma-Pipeline by United Therapeutics Corporation, H1 2015 74

Assessment by Monotherapy Products, H1 2015 75

Assessment by Combination Products, H1 2015 76

Number of Products by Stage and Target, H1 2015 78

Number of Products by Stage and Mechanism of Action, H1 2015 83

Number of Products by Stage and Route of Administration, H1 2015 87

Number of Products by Stage and Molecule Type, H1 2015 89

Neuroblastoma Therapeutics-Recent Pipeline Updates, H1 2015 230

Neuroblastoma-Dormant Projects, H1 2015 293

Neuroblastoma-Dormant Projects (Contd..1), H1 2015 294

Neuroblastoma-Dormant Projects (Contd..2), H1 2015 295

Neuroblastoma-Discontinued Products, H1 2015 296

List of Figures

Number of Products under Development for Neuroblastoma, H1 2015 17

Number of Products under Development for Neuroblastoma-Comparative Analysis, H1 2015 18

Number of Products under Development by Companies, H1 2015 19

Number of Products under Investigation by Universities/Institutes, H1 2015 24

Comparative Analysis by Late Stage Development, H1 2015 26

Comparative Analysis by Clinical Stage Development, H1 2015 27

Comparative Analysis by Early Stage Products, H1 2015 28

Assessment by Monotherapy Products, H1 2015 75

Number of Products by Top 10 Targets, H1 2015 77

Number of Products by Stage and Top 10 Targets, H1 2015 77

Number of Products by Top 10 Mechanism of Actions, H1 2015 82

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 82

Number of Products by Top 10 Routes of Administration, H1 2015 86

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 86

Number of Products by Top 10 Molecule Types, H1 2015 88

Number of Products by Stage and Top 10 Molecule Types, H1 2015 88

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Ability Pharma, SL

Acetylon Pharmaceuticals, Inc.

Advanced Accelerator Applications SA

Aeterna Zentaris Inc.

Ampio Pharmaceuticals, Inc.

APEIRON Biologics AG

Aptose Biosciences Inc.

AstraZeneca Plc

Bellicum Pharmaceuticals, Inc.

Bexion Pharmaceuticals, LLC.

BioLineRx, Ltd.

Bionucleon Srl

Cebiotex, S.L.

Celgene Corporation

Chugai Pharmaceutical Co., Ltd.

Cleveland BioLabs, Inc.

CureFAKtor Pharmaceuticals, LLC

DEKK-TEC, Inc.

Errant Gene Therapeutics, LLC

F. Hoffmann-La Roche Ltd.

Gamida Cell Ltd.

Ignyta, Inc.

Juno Therapeutics Inc.

Lindis Biotech GmbH

MabVax Therapeutics Holdings, Inc.

Merck & Co., Inc.

Merrimack Pharmaceuticals, Inc.

Netris Pharma S.A.S.

Novartis AG

Novogen Limited

Pono Pharma

Progenics Pharmaceuticals, Inc.

Recombio S.L

Sareum Holdings Plc

Shionogi & Co., Ltd.

Sutro Biopharma, Inc.

Teva Pharmaceutical Industries Limited

Threshold Pharmaceuticals, Inc.

United Therapeutics Corporation

Neuroblastoma Therapeutic Products under Development, Key Players in Neuroblastoma Therapeutics, Neuroblastoma Pipeline Overview, Neuroblastoma Pipeline, Neuroblastoma Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com